Pfizer (PFE) Payables (2009 - 2026)

Pfizer (PFE) has 18 years of Payables data on file, last reported at $4.5 billion in Q1 2026.

• Payables for Q1 2026 came in at $4.5 billion, down 14.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (down 14.01% YoY), and the FY2025 annual result was $7.7 billion, down 4.77% from the prior year.
• Payables eased to $4.5 billion in Q1 2026 per PFE's latest filing, from $7.7 billion in the prior quarter.
• Over five years, Payables peaked at $9.1 billion in Q4 2022 and troughed at $4.5 billion in Q1 2026.
• A 5-year average of $6.9 billion and a median of $7.5 billion in 2024 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2023: Payables jumped 35.48% in 2022, then tumbled 37.29% in 2023.
• A 5-year view of Payables shows it stood at $9.1 billion in 2022, then fell by 0.33% to $9.1 billion in 2023, then declined by 11.14% to $8.1 billion in 2024, then fell by 4.77% to $7.7 billion in 2025, then tumbled by 41.37% to $4.5 billion in 2026.
• Business Quant data shows PFE's Payables at $4.5 billion in Q1 2026, $7.7 billion in Q4 2025, and $5.0 billion in Q3 2025.